Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 9Plasma cell 7Other hematologic neoplasm 7Sarcoma 5Myeloid 5Dermatologic 3Other neoplasm 2Classical hematology 2Other solid neoplasm 1Genitourinary 1CNS 1

Conditions

Unspecified Childhood Solid Tumor, Protocol Specific 1

Interventions

Cisplatin 70Paclitaxel 68pembrolizumab 65Carboplatin 61Irinotecan 59Injections 53Gemcitabine 53Docetaxel 49Fluorouracil 35Cyclophosphamide 35Pemetrexed 34Oxaliplatin 31Capecitabine 30Bevacizumab 29Leucovorin 27atezolizumab 23Nivolumab 23tislelizumab 19Etoposide 18Cetuximab 17durvalumab 16Temozolomide 16Bortezomib 16alvocidib 15Topotecan 15olaparib 14Sorafenib 14Rifampin 14Itraconazole 14Erlotinib Hydrochloride 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Methylprednisolone × Other solid neoplasm × Clear all
NCT00436761 2013-12-18

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

National Cancer Institute (NCI)

Phase 1 Unknown
20 enrolled
Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡